Recursion (@RecursionPharma) header
Recursion (@RecursionPharma) profile picture

Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.

SLC, London, NYC, Montreal
Joined July 2014
Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)Photo by Recursion (@RecursionPharma)
Today, Recursion announced that it has aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for the treatment of familial adenomatous polyposis (FAP). FAP is a rare, inherited disease that affects more than 50,000 patients in the US and EU5. Colectomy does not end the disease. Patients face lifelong endoscopic surveillance, repeated polyp removal and, for some, further major surgery. REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion’s AI foundation models. Recursion achieved a key regulatory milestone with FDA alignment on a composite event-free survival primary endpoint that includes a novel, clinically meaningful component: excision of an adenoma ≥10 mm throughout the GI tract will count as an event. This is of particular importance because adenomas of this size are associated with an increased risk of high-grade dysplasia and cancer. They occur regularly over the course of the disease in both the upper and lower GI tract. By counting qualifying excisions in either region as events, the primary endpoint captures a common and consequential intervention across FAP care. Our Ph2 TUPELO data gave us a strong foundation for our discussions. Presented at CGA-IGC on November 2, 2026, nearly 1 in 2 patients in the upper GI achieved polyp burden reductions of 65% or more, and two patients achieved reductions of 98% or more in the upper GI. No new safety signals were observed. The trial is expected to enroll approximately 200 adults with FAP following colectomy or proctocolectomy and is on track to begin in the second half of 2027. Full release: ir.recursion.com/news-releas… #RareDisease #FAP #AIDrugDiscovery
3
12
9
69
7,047
We’re headed to London Life Sciences Week & the @Jefferies Global Healthcare Conference! Catch the Recursion team on stage throughout the week: 🔷Mon, Nov 16 @ 10:20 AM: CSO Dave Hallett joins the Frontiers of Life Sciences Fireside Chat, “The AI Revolution in Drug Discovery,” hosted by @MedCityHQ and London & Partners 🔷Tues, Nov 17 @ 12:45 PM: CFO & President of Recursion UK Ben Taylor joins @FierceBiotech to discuss using AI in drug discovery to identify better targets and build stronger pipelines. 🔷Wed, Nov 18 @ 9:00 AM: CSO Dave Hallett returns for the Intelligence Era panel, “Beyond the Hype: Building the Next Generation of Biotechnology,” hosted by True Search, @FlagshipPioneer, and ARCH Venture Partners 🔷Wed, Nov 18 @ 5:00 PM: CEO & President Najat Khan closes out our sessions with a Fireside Chat at the @Jefferies Global Healthcare Conference. Webcast: event.summitcast.com/view/av… See you there! #LLSW #JefferiesHealthcare
3
4
2
22
2,721
We’ll be at this year’s EORTC-NCI-AACR (ENA) Symposium on Nov 19th in Barcelona. Recursion’s Erik Müllers will be presenting on REC-7735: an AI precision-designed, oral PI3Kα H1047R inhibitor which targets a key oncogenic driver in multiple solid tumors, including breast, colorectal, endometrial, and ovarian cancers. REC-7735 selectively targets PI3Kα H1047R while sparing wild-type, and offers the potential to overcome the limitations of current PI3Kα inhibitors. Key preclinical findings highlighted in the poster include: 🔍 >100-fold selectivity for H1047R over wild-type PI3Kα. 🚀 Efficacy across multiple solid tumor models in vivo. ✅ In contrast to non-selective and moderately selective inhibitors, REC-7735 did not impact blood glucose, insulin levels, or other metabolic markers in naïve or diabetic animals, even at supra-efficacious doses. Come check us out! For more information about REC-7735, see below: cdn.prod.website-files.com/6…
1
5
3
29
4,977
Recursion Q3 Update: New REC-4881 Data from CGA-IGC, Partner Milestones, and Runway into 2029 Yesterday we reported our third quarter results, and this morning we walked through them live from CGA-IGC in Denver. Together they show consistent delivery across our three core capabilities: uncovering novel biology, designing differentiated molecules against challenging targets, and generating clinical evidence that matters for patients. 🚀 Deliver | New TUPELO data presented by Dr. Lisa Boardman of Mayo Clinic at CGA-IGC show deep, durable polyp burden reductions with REC-4881 in FAP, across the upper and lower GI tract and in larger, higher-risk polyps. After 12 weeks of treatment, 87% of patients saw a reduction in total polyp burden, and 85% of evaluable patients remained below baseline 12 weeks after stopping. Two patients saw their counts of larger polyps fall from more than 90 to one. With REC-1245, built on a novel target surfaced by our platform, we have seen encouraging early responses in heavily pretreated patients and selected the 45 mg dose for expansion cohorts, including endometrial cancer. 🚀 Design  | Sanofi optioned our first development candidate—a potential first-in-class oral dual-targeting inhibitor in immunology. Phase 1 is expected in 2027. It is the sixth milestone across our Sanofi collaboration and the ninth across our partnered programs in the past two years. 🚀 Discover | Genentech advanced the first previously unexplored neuroscience target from the maps we built together with Roche and Genentech into an early discovery program. Further validating our platform, Roche recently highlighted a novel mechanism for a previously “undruggable” cancer pathway discovered with our biology engine, noting it would not have been discovered “without AI-powered large-scale phenotypic screens.” We are building this momentum from a position of greater focus and discipline. Following our recent $200 million offering, we have extended our expected cash runway into 2029. Upcoming catalysts include details on the registrational path for REC-4881 later this year, a registrational trial targeted for the second half of 2027, and the start of Sanofi’s Phase 1 study in 2027. As we enter this next chapter, we are also thrilled to welcome Fred Hassan as Chair of our Board. Fred brings more than four decades of experience leading, transforming, and advising across our industry, providing invaluable perspective on what it takes to move medicines from clinical proof of concept through approval, launch, and ultimately to patients. Most importantly, today was a reminder of why we do this work. We are deeply grateful to our employees, collaborators, clinical investigators, investors, and the patients and families who joined our webinar to share their experiences. More information below: Q3 Full Release: ir.recursion.com/news-releas… FAP Webinar: recursion.com/fap-webinar CGA-IGC Data: ir.recursion.com/news-releas…
4
7
1
36
4,759
Join us on November 3, 2026 at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT for our Q3 2026 Earnings Call + FAP Webinar where we'll provide business updates and report our third quarter 2026 financial results. Broadcasting live from CGA-IGC, the event will feature a presentation on updated REC-4881 data, followed by dedicated KOL and patient panels focused on the unmet need in FAP. teapawt.org/i/broadcasts/2BlMKndVo… Questions may be submitted at: forms.gle/4yd2GdH3mN8pFGri7
1
1
24
2,767
Recursion will host its third quarter financial results and business updates in a combined Earnings Call and special FAP Webinar on November 3, 2026 at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT. Broadcasting live from CGA-IGC, the event will feature REC-4881 data from the company’s CGA-IGC presidential plenary presentation, followed by dedicated KOL and patient panels. Join the call on: LinkedIn: linkedin.com/company/recursi… YouTube: youtube.com/@RecursionPharma… X: teapawt.org/RecursionPharma Analysts, investors, and the public have the opportunity to ask questions via the form here: forms.gle/3aNgEeVHjjbrhzi36 More information here: ir.recursion.com/news-releas…
1
6
3
33
4,133
"This is only possible because we control the design, make, and test steps within one connected system rather than handing off between disconnected tools and teams." Once molecules are designed in silico, they must be synthesized and tested in the real world. In Part 7 of our platform series, VP of Pharmacology Martin Redhead, Ph.D., explains how these candidate designs move directly into our automated DMTL (Design, Make, Test, Learn) labs. Recursion’s automated chemistry platform goes far beyond simple one-pot reactions. We execute complex, multi-step medicinal chemistry at scale. Advanced automation handles the workup, purification, and digital sample tracking for thousands of compounds, creating a digital record of every single experiment. Our in-house AI agents take this a step further by actively helping scientists plan efficient synthetic routes. Because we control the entire design, make, and test lifecycle within one fully integrated system, we completely eliminate the friction and time lost handing off data between disconnected teams. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #ComputationalChemistry #DrugDiscovery #MachineLearning
4
11
2
49
167,816
Recursion Announces New Clinical Data Across Two Potential First-in-Class Programs, Sanofi Partnership Milestone, and Oversubscribed $200M Offering Today, we announced important progress across our clinical pipeline, partnerships, and capital position—reflecting growing evidence of what our integrated AI-enabled drug discovery platform can deliver. 🚀 REC-4881 | Deep, durable polyp reductions in FAP In an expanded adult population (18+), 87% of patients achieved polyp burden reductions after 12 weeks (47% median), with 85% remaining below baseline after 12 weeks off treatment. In the upper GI—the area of greatest unmet need—92% achieved reductions (55% median), including two patients with near-complete reductions (≥98%). Of those with reductions, 92% remained below baseline after 12 weeks off treatment. With no approved pharmacologic therapies for FAP, we are targeting registrational trial initiation in 2H 2027, pending FDA discussions. Full data will be presented November 2 at CGA-IGC. 🚀 REC-1245 | Encouraging early activity in heavily pretreated cancer patients Our potential first-in-class oral RBM39 degrader demonstrated three partial responses (two confirmed in endometrial cancer; one unconfirmed in liver cancer) and 91.7% disease control (11/12) at doses ≥45 mg. No dose-limiting toxicities or treatment-related serious adverse events were observed at the selected 45 mg expansion dose. 🚀 Sanofi | First development candidate optioned Two challenging targets, one oral molecule. A potential first-in-class candidate for inflammatory disease, enabled by Recursion’s AI platform and small-molecule chemistry capabilities alongside Sanofi’s expertise. Phase 1 expected in 2027, marking the sixth progress-based milestone across our collaboration. 🚀 $200M Oversubscribed Follow-On Offering | Extending Runway Into 2029 Broad demand from leading healthcare specialists, long-only institutions, and growth investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management. The financing supports advancement of our clinical pipeline, continued AI engine innovation, and strategic partnerships. Multiple independent proof points. Across diseases, programs, and partnerships. Powered by one integrated AI-enabled engine. Thank you to our employees, collaborators, clinical investigators, patients, and investors who make this progress possible. Links below 👇 Business Update: ir.recursion.com/news-releas… Sanofi announcement: ir.recursion.com/news-releas… Public offering: ir.recursion.com/news-releas…
4
17
14
98
636,641
"Our integrated system narrows millions of molecules down to a short list that's synthetically accessible. Not just promising in silico, but actually makeable before a single one is sent to the labs." Traditional drug design often leans on decades of precedent and familiar chemistry. In Part 6 of our platform series, SVP of Drug Design Donovan Chin, Ph.D., explains how Recursion breaks that mold by getting a full computational design cycle up and running in about a day. Our AI-native engine vastly increases the aperture for our chemists. Instead of relying solely on known binding pockets, they can efficiently explore entirely novel and complex chemical space. By leveraging our integrated data, the team can forecast non-obvious design hypotheses and predict how to synthesize molecules even when nothing like them currently exists. This process begins by scoring binding affinity using advanced 3D structural models like Nesso-1. From there, the team runs hundreds of integrated models covering ADME, potency, advanced simulations, and AI retrosynthesis. This unified system rapidly filters millions of potential molecules down to a precise shortlist of high-quality candidates that are physically ready for the lab. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #ComputationalChemistry #DrugDiscovery #MachineLearning
8
8
1
73
1,091,814
Thanks to @nathanbenaich and @airstreet for their annual State of AI Report. We’re happy to be included for our work on REC-4881, a MEK1/2 inhibitor currently in Phase 2 clinical trials for FAP. Also featured is Nesso-1: an open-source model that predicts binding affinity in seconds to unlock faster early-stage drug discovery.
welcome to the 9th annual @stateofai report! ai building better ai, world models, physical ai, geopolitics, cyber defense and 12-month predictions. read it at stateof(dot)ai or watch my editor’s cut here. a few of this year’s biggest findings follow:
2
3
2
40
4,005
"Across our programs, we've advanced quality novel candidates after synthesizing only around 300 compounds, roughly 90% fewer than the industry average." Now that we have mapped the biology, we need to design the exact molecule to target it. In Part 5 of our platform series, SVP of Drug Design Donovan Chin, Ph.D., and VP of Pharmacology Martin Redhead, Ph.D., break down how we transition from biological target discovery to navigating complex chemical space. Just like our approach to biology, we solve chemistry problems through a continuous feedback loop between computation and experimentation. Before a single molecule is ever synthesized in the lab, our team uses Centaur, our integrated drug design environment. By combining hundreds of machine learning and physics-based models into a single platform, we can iteratively design novel molecular structures starting directly from target properties. This generative de novo design approach automatically updates our models so they improve with every single cycle. Our AI-native product engine has already produced over 10 development candidates. By holding our chemistry to the same rigorous standards as our biology, we can synthesize a fraction of the traditional compound volume while delivering superior novel molecules. We believe this focus on quality and novelty over sheer volume will define the true impact of AI on drug development. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #AIDrugDiscovery #DrugDiscovery #Chemistry
6
9
2
83
1,018,488
Najat Khan, CEO of Recursion, will speak at Quorum, a healthcare AI leaders forum co-hosted by Flare Capital Partners and Google for Startups on Oct 14. Najat will be featured on the panel “From Molecule to Market: AI and the Future of Pharma R&D.” She will join Melisa Tucker, Chief Data Officer at Tempus AI, and Zach Weinberg, Co-Founder & CEO at Curie.Bio., to discuss where AI is actually compressing drug discovery timelines, reshaping clinical trials, and rewriting R&D productivity. Learn more here: 👉gatsby.events/flarecapital-p… #TechBio #AI #AIdrugdiscovery
3
3
2
41
3,900
"A hypothesis from a model isn't a discovery yet. So, it goes back into the lab. The biology the model predicted is the biology we saw at the bench." A computational prediction alone does not cure a disease. In Part 4 of our platform series, Associate Principal Scientist Celia Fernandez explains how Recursion closes the loop to turn AI generated hypotheses into validated biological targets. Once our foundation models point to a potential target, we run the lab in the opposite direction. The hypothesis enters a validation cascade that becomes progressively more demanding and highly specific to the disease. This physical testing allows us to aggressively derisk our computational discoveries directly at the bench. We test these targets against the exact same high bar that our global pharma partners hold their own internal programs to. When the loop finally closes, we can confidently prove that the biology the machine learning model predicted matches the physical reality we see in the lab. 🚀Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #AIdrugdiscovery #AI #drugdiscovery
7
9
2
87
1,014,616
“The data is used to train our models. The models point to the targets. That’s lab-in-the-loop.” Generating millions of data points is only the first step. You need immense computational power to make sense of it (and maybe a good pair of headphones, because BioHive-2 is loud). In Part 3 of our series on our end-to-end platform, Chief Technology Officer Ben Mabey explains how Recursion turns raw data into a novel view of biology. 🖥️Using BioHive-2, one of the fastest supercomputers in the world, we train state-of-the-art foundation models to process every image and sequence we generate. These models create a unique embedding, or fingerprint, for every cellular perturbation we have ever performed. All of this high-dimensional data is compiled into a single massive dataset to form a comprehensive map of biology. By comparing known disease fingerprints against this map, we can find other genetic manipulations that create similar effects. This allows us to identify targets that drive or rescue a disease state, generating new hypotheses and pointing us towards potential novel discoveries. 🚀Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #AI #drugdiscovery #AIdrugdiscovery #biology
3
8
3
40
59,766